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Abstract: The role of genetic testing over the clinical and functional variables, including data from 
the cardiopulmonary exercise test (CPET), in the hypertrophic cardiomyopathy (HCM) risk 
stratification remains unclear. A retrospective genotype–phenotype correlation was performed to 
analyze possible differences between patients with and without likely pathogenic/pathogenic (LP/P) 
variants. A total of 371 HCM patients were screened at least for the main sarcomeric genes MYBPC3 
(myosin binding protein C), MYH7 (β-myosin heavy chain), TNNI3 (cardiac troponin I) and TNNT2 
(cardiac troponin T): 203 patients had at least an LP/P variant, 23 patients had a unique variant of 
uncertain significance (VUS) and 145 did not show any LP/P variant or VUS. During a median 5.4 
years follow-up, 51 and 14 patients developed heart failure (HF) and sudden cardiac death (SCD) 
or SCD-equivalents events, respectively. The LP/P variant was associated with a more aggressive 
HCM phenotype. However, left atrial diameter (LAd), circulatory power (peak oxygen uptake*peak 
systolic blood pressure, CP%) and ventilatory efficiency (C-index = 0.839) were the only 
independent predictors of HF whereas only LAd and CP% were predictors of the SCD end-point 
(C-index = 0.738). The present study reaffirms the pivotal role of the clinical variables and, 
particularly of those CPET-derived, in the HCM risk stratification. 
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1. Introduction 
Hypertrophic cardiomyopathy (HCM), the most common genetic heart disease, inherited with 
an autosomal dominant pattern, incomplete penetrance and variable expressivity, is characterized by 
markedly different instrumental and clinical spectra [1–3]. Accordingly, there is always great interest 
in investigating approaches potentially able to identify early those HCM patients at high risk of 
cardiovascular events both in terms of sudden cardiac death (SCD) and heart failure (HF). Indeed, 
albeit the SCD is a devastating but relatively rare event, HF development and its related 
complications still represent an incoming concern in HCM patients [4–6]. 
In such a context, due to its genetic nature, many researchers attempted not only an HCM 
genotype–phenotype correlation but also a possible genotype-based risk stratification. Indeed, HCM 
is predominantly a sarcomeric disease and variants in MYH7 and MYBPC3 genes, encoding for the 
cardiac thick myofilament proteins β-myosin heavy chain and myosin binding protein C, 
respectively, together account about 50% of the HCM families. Conversely, likely 
pathogenic/pathogenic (LP/P) variants in thin filament protein genes, such as TNNT2, TNNI3 and 
TPM1 encoding for cardiac troponin T, troponin I and alpha-tropomyosin, account for less than 10% 
[6–9]. Several studies have demonstrated that being carriers of sarcomeric variants might exert a 
negative prognostic impact on outcome, as well as multiple simultaneous variants, such as the so-
called “gene dosage effect” [8–13]. What remains unclear, up to now, is whether the genetic profile 
of the single HCM patient might provide a real significant incremental risk prediction beyond the 
clinical risk factors, including those derived from a maximal cardiopulmonary exercise test (CPET) 
[2,3]. Indeed, growing evidence suggests that a CPET assessment, combined with other clinical and 
instrumental variables, represents a useful tool in stratifying both the SCD and the HF-related events’ 
risk in HCM patients [14–18]. 
Therefore, the current multicenter retrospective study investigates a possible adjunctive role of 
genetic testing analysis in the HCM patients’ management over the main clinical and functional 
parameters. Particularly, a genotype–phenotype correlation was performed to analyze possible 
differences between HCM patients with and without LP/P variants with respect to their main clinical 
and functional features and, mainly, their SCD and HF-related events’ rate. 
2. Methods 
2.1. Study Sample 
Data from a total of 665 consecutive outpatients with HCM were analyzed. All patients were 
part of a cohort recruited and prospectively followed in three HCM Italian centers between 
September 2007 and December 2019: Azienda Ospedaliera Universitaria Sant’Andrea, “Sapienza” 
University, Rome (n = 437); Azienda Ospedaliera San Camillo Forlanini, Rome (n = 189); Centro 
Cardiologico Monzino, University of Milan, Milan (n = 39). The diagnosis of HCM was based on 
maximal wall thickness (MWT) ≥ 15 mm unexplained by abnormal loading conditions or in 
accordance with published criteria for the diagnosis of disease in relatives of patients with 
unequivocal disease [2,3]. Patients with known metabolic diseases or syndromic causes of HCM were 
excluded from the present study. 
The study complied with the ethical standards of the Declaration of Helsinki and was reviewed 
and approved by the institutional ethics committees. Written informed consent was obtained from 
all participants. The authors from each participating center guarantee the integrity of data from their 
institution and have agreed to the article as written. 
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2.2. Patients Clinical and Functional Assessment 
Data were independently collected at each participating center using a uniform methodology. 
Each HCM patient underwent a clinical assessment, including history with pedigree analysis and the 
New York Heart Association (NYHA) classification, 24 h ECG Holter monitoring, transthoracic 
Doppler echocardiography and maximal CPET. The usual five SCD risk factors were also collected 
[2,3]: (a) FH-SCD (history of HCM-related SCD in at least one first-degree or other relatives younger 
than 50 years old); (b) massive left ventricular (LV) hypertrophy (maximal wall thickness, MWT, ≥ 30 
mm); (c) at least one run of nonsustained ventricular tachycardia (NSVT, ≥ 3 consecutive ventricular 
beats at a rate of ≥ 120 beats per minute and < 30 s in duration on 24 h ECG Holter monitoring); (d) 
unexplained syncope judged inconsistent with neurocardiogenic origin; (e) abnormal blood pressure 
response to exercise (ABPRE, failure to increase systolic blood pressure, SBP, by at least 20 mm Hg 
from rest to peak exercise or a fall of ≥ 20 mm Hg from SBP) 
The following echocardiographic measurements, obtained according to the international 
guidelines [19], were considered: LV end-diastolic diameter (LVEDd, parasternal long axis), the 
greatest LV thickness (MWT, measured at any LV site), left atrial diameter (LAd, parasternal long 
axis), the highest maximal LV outflow tract gradient among those measured at rest, in orthostatic 
position and after Valsalva maneuver (LVOTGmax, apical four-chamber view) [20] and LV ejection 
fraction with Simpson’s biplane methods (LVEF, apical four-chamber view). 
All CPETs were performed using an electronically braked cycle ergometer. A personalized ramp 
exercise protocol was performed, aiming at a test duration of 10 ± 2 min [21]. The exercise was 
preceded by a few minutes of resting breath-by-breath gas exchange monitoring and by an unloaded 
warm-up. In the absence of clinical events, CPET was interrupted when patients stated that they had 
reached maximal effort. A 12-lead ECG, diastolic and systolic blood pressure were recorded during 
CPET, in order to obtain the following parameters: rest heart rate (HR), peak HR, %pHR ((peak 
HR/(220−age)) × 100), and ΔSBP (peak SBP−rest SBP) [22]. A breath-by-breath analysis of expiratory 
gases and ventilation (VE) has been performed, and peak values were obtained in the last 20 s of 
exercise. The predicted peak VO₂ was determined by using the gender-, age- and weight-adjusted 
formula. Circulatory power (CP = peak VO₂ × SBP) was obtained considering peak VO₂ value as a 
percentage of predicted (CP%) [19,23]. Anaerobic threshold (AT) was measured by V-slope analysis 
of VO₂ and VCO₂, and it was confirmed by ventilator equivalents and end-tidal pressures of CO₂ and 
O₂ [24]. The end of the isocapnic buffering period was identified when VE/VCO₂ increased and the 
end-tidal pressure of CO₂ decreased. VE/VCO₂ slope was calculated as the slope of the linear 
relationship between VE and VCO₂ from the 1st minute after the beginning of the loaded exercise 
and the end of the isocapnic buffering period [24]. 
2.3. Genetic Testing 
All patients included in the study received genetic counseling and underwent genetic testing for 
HCM, performed by Sanger sequencing (from 2007 to 2010) or NGS (next-generation sequencing, 
from 2011 to 2019). The genes analyzed in the participating laboratories from the HCM centers had 
changed and/or added over time. In this retrospective study, we report the genotype–phenotype 
correlation analysis only for those patients screened at least for the sarcomeric genes MYBPC3 
(myosin binding protein C, cardiac) MYH7 (β-myosin heavy chain, cardiac), TNNI3 (troponin I, 
cardiac) and TNNT2 (troponin T type 2, cardiac). All coding regions and boundaries of flanking 
introns ± 25 were analyzed for all genes considered in this study. In addition, all variants reported in 
this paper, identified by NGS technology, were validated by Sanger sequencing. Patients with 
variants located in nonsarcomeric genes were also excluded. 
All the identified variants were re-evaluated based on new evidence from the scientific literature 
and classified according to the criteria of the American College of Medical Genetics and Genomics 
(ACMG) [25,26]. Only the genetic variants predicted to alter the protein and with a minor allele 
frequency (MAF) ≤ 0.2% (considering the prevalence of HCM disease in the general population), were 
considered. For this evaluation, we used MAF data derived from GnomAD (Genome Aggregation 
Database https://gnomad.broadinstitute.org/). The clinical classification of variants was carried out 
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according to the 5-class system: benign (B), likely benign (LB), likely pathogenic (LP), pathogenic (P) 
and variants of uncertain significance (VUS). Genetic results were considered informative for LP or 
P variants, noninformative for B, LB or VUS variants. Variants are reported using the Human 
Genome Variation Society nomenclature guidelines (https://varnomen.hgvs.org/). 
2.4. Clinical Outcomes 
All patients had planned clinical reviews every 6–12 months or earlier according to the clinical 
status. Follow-up duration was defined as the time interval between the clinical examination and 
either the first event or the last visit/telephone interview in case of no events. 
The HF end-point was represented by the following events: death due to HF, cardiac 
transplantation, progression to a stable NYHA class III–IV due to an end-stage phase with or without 
LVEF < 50% (hypokinetic dilated phase or restrictive phenotype evolution), severe functional 
deterioration leading to hospitalization for septal reduction, hospitalization due to HF symptoms or 
signs development. The SCD end-point was also tested, which included SCD or an equivalent event. 
SCD was defined as witnessing sudden death with or without documented ventricular fibrillation or 
death within 1 h of new symptoms or nocturnal deaths with no antecedent history of worsening 
symptoms. Aborted SCD during follow-up and appropriate ICD therapies (defined as intervention 
triggered by ventricular fibrillation or rapid ventricular tachycardia at > 180 bpm) were considered 
equivalent to SCD in accordance with previous studies [17,18,27,28]. 
The causes of death, as well as the other events, were ascertained by experienced cardiologists 
at each center using hospital and primary health care records, death certificates, post-mortem reports, 
and interviews with relatives and/or physicians. To avoid a composite cardiovascular end-point 
including also cerebrovascular events, due to the small number of such events and in accordance 
with other studies by our research group [17,18,22], death due to ischemic or hemorrhagic stroke (n. 
2 events) and nonfatal cerebrovascular (n. 5 events), as well as death due to noncardiovascular causes 
(n. 2 events), were excluded from the survival analysis. 
2.5. Statistical Analysis 
All data are expressed as mean ± standard deviation or as absolute number (percentage). 
Preliminarily, an extension of the Shapiro–Wilk test of normality was performed. Categorical 
variables were compared with a difference between proportion tests whereas a two-sample t-test was 
used to compare the continuous data between the two study groups (no variants and VUS Versus 
LP/P variants). In comparing the two populations, the variance was estimated separately for both 
groups and the Welch–Satterthwaite modification to the degrees of freedom was used. 
We, therefore, focused on the distribution of survival times by adopting the Cox proportional 
hazards regression model. We performed a backward selection of the predictors to be included in the 
model. A 5% significance level was used in the backward elimination procedure to select covariates 
for the final multivariate model for the combined as well as the HF end-point while, due to the low 
events’ number, a 15% significance level was adopted for the SCD one. To avoid the inclusion of 
collinear variables in the multivariate Cox analysis, we built several models in which VO₂-derived 
variables, known to be collinear, were added to the prognostic model one at a time. We retain the 
model with the best trade-off between model complexity and model fit judged by the log-likelihood. 
We also performed a calibration analysis. We computed the average calibration error for both 
approaches and tested the observed versus average predicted probabilities for each class of risk. The 
Brier quadratic error score and a χ² test of goodness of fit based on the Brier score were also checked. 
We did not find any clear indication of overfitting from the post hoc analysis and, consequently, in 
the present paper we simply reported results based on the backward elimination procedure only. 
Discrimination of variables included in the final multivariate model specification was performed by 
Harrell’s C-index. Therefore, we investigated the proportional hazards assumption by tests and 
graphical diagnostics based on scaled Schoenfeld residuals. Test of proportional hazards assumption 
for each covariate was obtained by correlating the corresponding set of scaled Schoenfeld residuals 
with the Kaplan–Meier estimate of the survival distribution. To check for the presence of influential 
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observations, we produced a matrix of estimated changes in the regression coefficients upon deleting 
each observation in turn and comparing the magnitudes of the largest values to the regression 
coefficients. 
Statistical analysis was performed using R (R Development Core Team, 2014). A p-value lower 
than or equal to 0.05 was generally considered as statistically significant. 
3. Results 
From an initial study sample of 665 consecutive HCM outpatients, a total of 294 patients (44%) 
were excluded because they did not undergo genetic testing (n = 197), because they were lost at 
follow-up (n = 39), because of the presence of nonsarcomeric variants (n = 22) or, eventually, because 
the genetic analysis was not performed according to the previously described inclusion criteria (n = 36). 
Thus, a total of 371 HCM patients were effectively enrolled and analyzed in the present study. The 
diagram displayed in Figure 1 resumes the step-by-step classification of the study population. 
  
Figure 1. Diagram showing the step-by-step classification of the hypertrophic cardiomyopathy 
(HCM) population considered in our study. LP/P: likely pathogenic/pathogenic sarcomeric variants; 
V.U.S.: variant of uncertain significance; CV: cardiac events; HF: heart failure; SCD: sudden cardiac 
death. 
3.1. Genetic Results 
Two hundred and three (55%) genetic tests were informative as they detected at least an LP/P 
variant, whereas the percentage of patients with VUS was 6% (n = 23 patients); 39% (n = 145 patients) 
did not show any P/LP variant or VUS (Figure 2). Excluding the B/LB variants, 124 unique variants 
were identified and detailed extensively in the Supplementary files (Tables S1 and S2). These variants 
included 91 (73%) missense, 2 (2%) intronic, 10 (8%) frameshift, 8 (6%) splicing, 11 (9%) nonsense, 1 
(1%) inframe variants (Figure S1). According to ACMG criteria, 94 variants were classified as LP/P 
and 30 of them as VUS. MYBPC3 and MYH7 resulted in the most mutated genes with 88 LP/P variants 
(75%, Figure 2). Twenty-four patients resulted to be carriers of multiple variants, considering those 
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with at least one P/LP variant and other P/LP or VUS variants (Table S3). Among these, 14 patients 
were double heterozygous with one variant in two different genes while the remaining 10 had 
multiple variants in the same gene. It was not possible to determinate the phase of these variants, 
since segregation studies among relatives could not be performed. 
 
Figure 2. Top panel: results of genetic testing analysis in the overall study sample. Bottom panel: type 
and distribution of likely pathogenic/pathogenic (LP/P) variants and variants of uncertain 
significance (VUS). MYL3: myosin light chain 3 ; TPM1: tropomyosin 1 ; TNNC1: troponin C1 ; ACTC1: 
actin alpha cardiac muscle 1; TNNI3: cardiac troponin I; TNNT2: cardiac troponin T; MYH7: β-myosin 
heavy chain; MYBPC3: myosin binding protein C. 
3.2. Clinical and Functional Characteristics  
The demographic and clinical data of the entire cohort are reported in Table 1. The population 
mainly consisted of middle-aged predominantly male (64%) patients with a quite preserved NYHA 
class (NYHA I–II 94%). At the study run-in, echocardiographic evidence of the end-stage phase was 
present in 4%, atrial fibrillation in 3% and a septal myectomy had been performed in 11% patients. 
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Documented cardiovascular comorbidities included systemic hypertension (27%), diabetes (6%) and 
coronary artery disease (4%). 
Table 1. Main clinical variables of the entire study sample at the study run-in (n = 371 patients). 
General Data  
Age, years 49 ± 16 
Male, n (%) 238 (64) 
Age at diagnosis, years 40 ± 19 
NYHA III–IV, n (%) 24 (6) 
ICD, n (%) 43 (12) 
Previous myectomy, n (%) 20 (5) 
SCD risk factors  
NSVT, n (%) 121 (32) 
FH-SCD, n (%) 48 (13) 
MWT > 30 mm, n (%) 26 (7) 
Unexplained syncope, n (%) 56 (15) 
ABPRE, n (%) 45 (16) 
Echocardiographic data  
LVEDd, mm 45 ± 5 
LAd, mm 43 ± 7 
MWT, mm 20 ± 5 
LVOT obstruction, n (%) 125 (33) 
LVOTGmax, mm Hg 11 (6–39) 
LVEF, % 62 ± 7 
CPET data  
Peak HR, % of predicted 79 ± 13 
Peak VO₂, mL/kg/min  23 ± 7 
Peak VO₂, % of predicted 77 ± 18 
Peak SBP, mmHg 164 ± 27 
CP%, % of predicted * mm Hg 12,937 ± 4300 
VE/VCO₂ slope 28.4 ± 5.5 
Medical treatment  
β-blocker, n (%) 228 (61) 
Nondihydropyridine CCB, n (%) 31 (8) 
ACE-I/ARB, n (%) 107 (29) 
Diuretics, n (%) 78 (21) 
Amiodaron, n (%) 33 (9) 
Data are expressed as mean ± SD, as an absolute number of patients (% on total sample) or as median 
(25th–75th percentile). VUS: variant of uncertain significance; LP: likely pathogenic; P: pathogenic; 
NYHA: New York Heart Association; ICD: implantable cardioverter defibrillator; SCD: sudden 
cardiac death; NSVT: nonsustained ventricular tachycardia; FH: family history; ABPRE: abnormal 
blood pressure response at exercise; LVEDd: left ventricular end-diastolic diameter; LAd: left atrial 
diameter; MWT: maximum wall thickness; LVOTGmax: maximal LV outflow tract gradient; LVEF: LV 
ejection fraction; SBP: peak systolic blood pressure; HR: heart rate; VO2: oxygen uptake; CP: 
circulatory power; VE/VCO2 slope: relation between ventilation versus carbon dioxide production; 
CCB: calcium channel blocker; ACE-I/ARB: angiotensin-converting enzyme inhibitors/angiotensin 
receptor blocker. 
Table 2 shows the comparison of clinical features between patients with and without LP/P 
variants. The LP/P variants group showed a younger age, a slightly higher prevalence of FH-SCD 
and ABPRE and a worse functional capacity in terms of pVO₂, CP% and VE/VCO₂ slope. With respect 
to the other clinical features, at the study run-in, the LP/P variants group had a greater prevalence of 
patients with end-stage phase (6% vs. 2%, p = 0.011) and atrial fibrillation (3% vs. 1%, p = 0.032), 
whereas no difference in the prevalence of previous myectomy was found (5% for both groups). 
Concerning the documented cardiovascular comorbidities, no difference was found in coronary 
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artery disease (3% vs. 5%), whereas the LP/P variants group showed a lower prevalence of systemic 
hypertension (15% vs. 31%, p < 0.001) and diabetes (3% vs. 8%, p = 0.007). 
Table 2. Main clinical variables of the study sample at the study run-in according to genetic testing 
results. 
General Data 
No Variants and VUS 
(n = 168) 
LP/P Variants  
(n = 203) 
p-Values 
Age, years 53 ± 18 45 ± 16 <0.001 
Male, n (%) 112 (67) 124(61) NS 
Age at diagnosis, years 47 ± 20 35 ± 17 <0.001 
NYHA III-IV, n (%) 10 (6) 14 (7) NS 
ICD, n (%) 11 (6) 32 (16) 0.019 
Previous myectomy, n (%) 9 (5) 11 (5) NS 
SCD risk factors    
NSVT, n (%) 48 (28) 73 (36) NS 
FH-SCD, n (%)  16 (9) 32 (16) 0.049 
MWT > 30 mm, n (%) 10 (6) 16 (8) NS 
Unexplained syncope, n (%) 29 (17) 26 (13) NS 
ABPRE, n (%) 11 (7) 34 (17) 0.003 
Echocardiographic data    
LVEDd, mm 46 ± 4 45 ± 6 NS 
LAd, mm 43 ± 7 43 ± 7 NS 
MWT, mm 20 ± 5 20 ± 5 NS 
LVOT obstruction, n (%) 79 (47) 45 (22) <0.001 
LVOTGmax, mm Hg 16 (9–39) 10 (5–33) 0.023 
LVEF, % 63 ± 4 61 ± 6 <0.001 
CPET data    
Peak HR, % of predicted 78 ± 12 79 ± 13 NS 
Peak VO₂, mL/kg/min 23 ± 7 23 ± 7 NS 
Peak VO₂, % of predicted 79 ± 18 75 ± 18 0.032 
Peak SBP, mmHg 175 ± 26 157 ± 26 <0.001 
CP%, % of predicted * mm Hg 14,070 ± 4269 12,015 ± 4020 <0.001 
VE/VCO₂ slope 27.5 ± 4.9 29.1 ± 6.0 0.019 
Medical treatment    
β-blocker, n (%) 105 (62) 122 (60) NS 
Non dihydropyridine CCB, n (%) 11 (7) 20 (10) NS 
ACE-I/ARB, n (%) 58 (34) 48 (24) 0.014 
Diuretics, n (%) 37 (22) 41 (21) NS 
Amiodaron, n (%) 16 (9) 17 (8) NS 
Data are expressed as mean ± SD, as the absolute number of patients (% on total sample) or as median 
(25th–75th percentile). NS: not significant. See Table 1 for other abbreviations. 
3.3. End-Point Analysis 
Median follow-up was 5.4 years (25th–75th centile: 2.3 to 8.1 years) with a total of 2271 patients-
year. During the entire follow-up, a total of 129 (35%) patients experienced at least one of the pre-
specified events. In patients who developed multiple events, time to the first was used as an event 
time cutoff and, accordingly, SCD or HF-related events at five-years’ cumulative hazard equal to 
0.369 was estimated. Patients who completed the follow-up period before the tenth year were 
censored at the time of the last clinical evaluation.  
A total of 14 SCD or SCD-equivalents were analyzed. Specifically, SCD occurred in three 
patients; four patients experienced a resuscitated SCD and seven patients had an appropriate ICD 
intervention. A total of 52 HF-related events were analyzed. Specifically, HF-related death occurred 
in two patients, seven patients underwent cardiac transplantation, 20 patients were hospitalized due 
to HF signs/symptoms, 12 patients were hospitalized for septal reduction procedure due to 
significant HF signs/symptoms development and 11 patients evolved to end-stage or restrictive 
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phenotype evolution. Table 3 reports the detailed Cox proportional univariate survival analysis for 
both the study end-points. Most of the single variables were significantly associated with the HF end-
point whereas few of them to the SCD end-point. Particularly, besides a number of clinical variables, 
the LP/P variant presence was significantly associated with the HF but not to the SCD end-point 
(Figure 3). Instead, at multivariate analysis, covariates showing significant effects for the primary 
HF-related end-point were the following: LAd, CP% and VE/VCO₂ slope (C-index 0.839, p < 0.001) 
while LAd and the CP% remained independently associated with the SCD end-point (C-index 
0.738, Table 4). 
Table 3. Main significant univariate Cox proportional survival analysis according to the clinical 
variables for the two main study end-points. 
 HF Endpoint (n = 52) SCD Endpoint (n = 14) 
 H.R. (95% C.I.) p-Values C-Index H.R. (95% C.I.) p-Values C-Index 
Age at CPET – NS – 0.964 (0.934–0.996) 0.038 0.613 
Male sex – NS – – NS – 
Age at diagnosis – NS – 0.944 (0.906–0.983) 0.006 0.729 
FH-SCD 1.869 (1.010–3.460) 0.046 0.522 2.830 (0.892–8.979) 0.077 0.607 
Unexplained Syncope – NS – – NS – 
NSVT 1.917 (1.102–3.333) 0.021 0.548 – NS – 
ABPRE 3.418 (1.769–6.605) <0.001 0.641 – NS – 
MWT > 30 mm – NS – 3.956 (1.210–12.940) 0.023 0.569 
MWT – NS – 1.100 (1.012–1.195) 0.025 0.593 
LVOTO 2.110 (1.215–3.664) <0.01 0.641 – NS – 
LAd 1.077 (1.039–1.116) <0.001 0.704 1.054 (0.984–1.129) 0.112 0.660 
LVOTGmax 1.016 (1.008–1.024) <0.001 0.672 0.971 (0.937–1.007) 0.123 0.577 
LVEF 0.929 (0.899–0.959) <0.001 0.587 – NS – 
pVO₂, mL/kg/min 0.851 (0.799–0.905) <0.001 0.739 – NS – 
pVO₂, % of predicted 0.851 (0.799–0.905) <0.001 0.749 – NS – 
VE/VCO₂ slope 1.017 (1.069–1.146) <0.001 0.724 – NS – 
CP% 0.998 (0.997–0.999) <0.001 0.778 0.998 (0.997–1.000) 0.052 0.705 
LP or P variants 2.395 (1.171–4.856) 0.013 0.609 – NS – 
H.R.: hazard ratio; C.I.: confidence interval. See Table 1 for other abbreviations. 
Table 4. Significant multivariate Cox proportional survival analysis and test for proportional hazards 
assumption for the two study end-points. 
 
Multivariate Cox Proportional Survival Analysis 
HF Endpoint SCD Endpoint 
 
 H.R. (95% C.I.) p-Values C-Index H.R. (95% C.I.) p-Values C-Index 
LAd 1.083 (1.039–1.130) <0.001 
0.839 
1.078 (1.005–1.163) 0.0485 
0.738 
CP% 0.998 (0.997–0.999) <0.001 0.998 (0.9996–1.000) 0.0488 
VE/VCO
₂ slope 
1.044 (0.999–1.090) 0.05   
See Tables 1 and 2 for other abbreviations. 
 
Figure 3. Kaplan–Meier estimator of survival free from heart failure (HF, left panel) and sudden 
cardiac death (SCD) related events according to the presence of likely pathogenic/pathogenic 
sarcomeric variants (PLV/PV). 
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4. Discussion 
The present multicenter retrospective study, conducted on a suitable cohort of consecutive HCM 
outpatients regularly followed at three Italian tertiary HCM centers, shows that HCM patients with 
LP/P sarcomeric variants tend to present a more aggressive form of disease with an earlier onset, a 
worse functional status and a greater risk of HF development and HF-related complications, 
compared to HCM patients with VUS or any variants. However, contextually, our data do not 
support a strict role of genetic testing over HCM patients’ comprehensive clinical assessment. Indeed, 
the LP/P variants presence does not emerge at multivariate analysis as an independent risk factor, 
being other instrumental variables (i.e., LAd, CP% and VE/VCO₂ slope) much stronger outcome 
predictors. 
Over the last decades a number of clinical features were investigated in order to identify those 
HCM patients at high risk of adverse events, both arrhythmic and HF-related. Indeed, albeit most of 
the cases show a benign course with a life expectancy equal to the general population [1], the SCD 
remains a rare but devastating event which is still the leading cause of death in the young population 
and athletes [2,3,6]. Furthermore, proper due to the improvement in the HCM management, both 
pharmacological and nonpharmacological (i.e., ICD, myectomy, LVAD/heart transplantation), there 
is a growing percentage of HCM patients who develop HF as well as HF-related complications 
[1,5,29]. The present study, as an ancillary result, confirms the abovementioned concern by showing 
a significant rate of HF-related events (n = 114 events) with a relatively low number of SCD and SCD-
equivalent (n = 14 events) at a midterm follow-up. 
Given the wide HCM clinical spectrum, its genetic nature and the need for targeted prevention 
strategies, previous studies sought to investigate and weigh the influence of sarcomere variants on 
the HCM clinical phenotype and outcome [7,8–13,16]. Indeed, HCM represents a sarcomeric disease 
with LP/P variants in MYBPC3 and MYH7 genes (thick filaments) together accounting for about 50% 
of the HCM families whereas LP/P variants in TNNT2, TNNI3 (thin filaments) accounting for less 
than 10% [1,6]. In such a context, an old study by Olivotto and colleagues, conducted in the pre-NGS 
scenario on a cohort of 203 HCM patients with a median follow-up of 4.5 years, suggested that HCM 
patients with sarcomere variants had a greater probability of a worse outcome (i.e., cardiac death, 
nonfatal stroke, end-stage progression) compared to those with nonsarcomeric variants [8]. A more 
recent study by Li and colleagues, on a sample of 558 HCM patients with a median follow-up of 4.5 
years, demonstrated that LP/P variants were associated to an early disease onset, to a high burden of 
established risk factors and, mainly, to a composite HF end-points (i.e., HF-related hospitalization, 
heart transplantation, HF-related death, progression to an end-stage phase) [10]. Further support to 
a possible role of genetic testing in the HCM risk stratification comes from Velzen and colleagues 
that, on a population of 626 HCM patients with a long-term follow-up (> 10 years), confirmed that 
patients with LP/P variants had a more aggressive phenotype (i.e., young age, high prevalence of 
SCD risk factors) and found an independent association with all-cause mortality, HF-related and SCD 
mortality [12]. Eventually, the recent SHARE study, conducted on a large cohort of 2763 HCM 
patients followed-up for a median of 2.9 years, confirmed that patients carrying sarcomeric LP/P 
variants had an earlier disease onset and a greater risk of developing the overall composite outcome 
(SCD or SCD-equivalent, LVAD/cardiac transplantation, progression to an end-stage phase, all-cause 
mortality, atrial fibrillation and stroke) [13]. The present study confirms that HCM patients carrying 
LP/P variants have a worse clinical feature in terms of disease onset as well as of historical risk factors 
[29]. However, we proved just a univariate association between the HCM-mutated status and a 
composite HF end-point. Although a close comparison with the abovementioned studies remains 
difficult because of different methodological approaches (i.e., number of genes screened, variants 
classification, end-points’ construction), the most likely reason underlying this negative datum could 
be the optimal clinical and functional characterization of our study cohort. Indeed, we specifically 
challenged the prognostic impact of LP/P variants not only with the historical variables but also, and 
specifically, with the CPET-derived parameters. Thus, we showed originally that patients with LP/P 
variants, although younger than the counterpart, exhibited also a more severe functional limitation 
both in terms of pVO₂ and ventilatory efficiency values. Furthermore, due to a concomitant blunted 
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increase of SBP during exercise, HCM patients with LP/P variants showed significantly lower values 
of CP%. Each of the three abovementioned CPET-derived variables has a specific pathophysiological 
meaning in the HCM patients’ context [30,31] and a possible capability as an outcome predictor. 
Particularly, the pVO₂ is a multidimensional parameter dependent on cardiac output (heart rate * 
stroke volume) and artero-venous O₂ extraction [24,32] and it has been extensively shown to be a 
strong predictor of poor outcome in HCM [14–18] as well as in HF patients [33,34]. The CP%, 
according to its formula [23,24], magnifies the prognostic power of the pVO₂ through the ABPRE 
[17,18] which, in turn, depends on the intrinsic myocardial function/geometry as well on abnormal 
peripheral autonomic reflexes [35,36]. Eventually, the ventilatory efficiency (i.e., VE/VCO₂ slope) has 
been shown to correlate with pulmonary capillary wedge pressure and left ventricular diastolic 
properties in HCM [37]. Although usually preserved in HCM patients, the VE/VCO₂ slope tends to 
worsen significantly only in the late systolic dysfunction phase but it is conceivable that it could 
mirror also an early exercise-induced left ventricular diastolic functional derangement [16,31,37–39]. 
5. Limitations 
The relatively small number of patients enrolled, together with the low number of hard events, 
represents a certain limitation that does not allow us to define the true weight of the genetic analysis 
results in terms of HCM risk prediction when compared to a full clinical assessment. However, it 
should be noted that our data do not argue against the overall importance of genetic testing in HCM 
management. Indeed, the identification of unaffected mutated relatives can be possible only after the 
detection of P/LP variants in affected HCM probands by gene sequencing [40]. Furthermore, 
molecular analysis of HCM genes remains one of the pivotal approaches in distinguishing the so-
called HCM phenocopies where early diagnosis is crucial to managing it optimally [2,3]. On the other 
hand, whenever a P/LP variant is not found in HCM patients, the HCM diagnosis should be carefully 
re-evaluated. Again, concerning risk stratification, a comprehensive clinical assessment might be 
essential. 
Another limitation that needs to be acknowledged is that, apart from the main four genes 
(MYBPC3, MYH7, TNNI3, TNNT2) that were tested in all patients, other genes known to be HCM-
related (i.e., ACTC1, TPM1, TNNC1, or MYL2 and MYL3) were tested in most but not all patients. 
However, it should be remarked that these variants are rarely detected in HCM patients [6,7]. 
Moreover, given the few numbers of patients carrying variants in thin filaments genes (< 15%) as well 
patients with multiple variants (6%) in our study sample, our survival analysis considered the overall 
impact of the LP/P sarcomeric variants without distinguishing the type of compromised filaments or 
a possible “gene dosage effect”. Similarly, growing data report possible relationships between 
specific variants location in functional domains of sarcomeric proteins and prognostic implications. 
Particularly, pathogenic missense variants located in the converter domain of the MYH7 gene were 
found associated with a worse outcome [41,42]. Furthermore, Garcia-Giustiniani and colleagues 
found a significant association between p.(Gly716Arg), p.(Arg719Trp) and p.(Arg719Gln) variants 
with a high risk of events (i.e., 50-year survival of only 20% of carriers) [43]. In the present study 
cohort, although six different pathogenic missense variants falling within the converter domain 
(p.(Gly716Arg), p.(Arg719Trp), p.(Arg719Gln), p.(Ile736Thr), p.(Gly741Arg) and p.(Arg723Cys)) 
were found, the small number of patients carrying these variants as well as their relatively young age 
unable us to support their specific prognostic power. For the same underlying reasons (i.e., small 
number of patients carrying VUS only), we cannot speculate about an intermediate prognosis in this 
subset of patients as hypothesized in the SHARE study [13]. Eventually, we found multiple variants 
in the same gene in 10 patients and in this specific setting, we cannot determinate whether the genetic 
alterations were on the same chromosome (heterozygous state) or not (compound heterozygous 
state). 
Finally, besides the genetic profile per se, we examined the prognostic effect of several clinical 
and instrumental variables at a single time point. Accordingly, we cannot exclude that changes in 
some variables, as for instance an upgrading of treatment during follow-up or upcoming risk factors, 
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altered our survival analysis. However, it is reasonable that seriate clinical and functional evaluations 
in HCM patients at the highest risk could further magnify our findings rather than rebut them. 
6. Conclusions 
Our data underline the importance of a multidimensional clinical assessment over the genetic 
testing analysis in the HCM risk stratification. This unexpected finding, different from other literature 
reports, might be likely explained by the limited size of the sample cohort. The LP/P variants were 
anyway associated with a more aggressive HCM phenotype in terms of early disease onset, high 
burden of historical risk factor and, for the first time, poor functional status. Of note, within a number 
of clinical and instrumental variables, the present study reaffirms the pivotal role of the variables 
derived from a CPET assessment. 
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